Skip to main content
Figure 2 | Molecular Cancer

Figure 2

From: Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression

Figure 2

Proliferation of resistant A375(DRO) cells: "resistant" cells were grown in 2% fetal bovine serum RPMI in the presence of 1 μmol/L of LGD1069, TZD or the combination for 9 days. Cell growth was analyzed using a nonradioactive cell proliferation assay. Proliferation was compared to that of cells grown in volume equivalent vehicle (DMSO – represented by the line) and resistant sublines were compared to the DMSO R control to assess the attenuation of response to receptor specific ligands. Proliferation was statistically significantly attenuated compared to the control DMSO R in all resistant cell lines and condition save for combination therapy in TZD R (p < 0.03). Columns, mean; bars, SEM.

Back to article page

Molecular Cancer

ISSN: 1476-4598